Close

BIO Board of Directors

In accordance with its Bylaws and Articles of Incorporation, the Biotechnology Innovation Organization (BIO) is governed by its Board of Directors.  The Full BIO Board of Directors is comprised of all the directors sitting on the Section Governing Boards, as described below. 

In addition, there is a Board Executive Committee that consists of the seven Elected Officers of the Organization, the immediate Past Chair of the Organization, the Vice Chairs of each Section's Governing Board, and At-Large Directors selected from the Full Board.

There are four Section Governing Boards organized by industrial sector and policy interest.  They are: (1) the Emerging Companies Section (ECS) Governing Board, (2) the Food & Agriculture (F&A) Section Governing Board, (3) the Health Section Governing Board, and (4) the Industrial & Environmental (I&E) Section Governing Board.  BIO’s four Section Governing Boards are comprised of thought leaders who bring their expertise to bear on major issues affecting their specific area of the biotechnology industry.

From time to time, each Section Governing Board may consider nominees to fill vacancies in accordance with BIO’s Bylaws and their own processes and criteria.  In general, BIO Board nominees should be the CEO or Chairman of the Board of a research and development (R&D) focused biotechnology company, but certain Governing Boards have alternative criteria, especially for larger companies.  To be considered for a BIO Board seat, a nominee typically has this type of affiliation with a BIO member company.  If your organization is not a BIO member, click below to learn more about membership.

BECOME A BIO MEMBER

If you are interested in nominating yourself or another person to fill a vacancy on the BIO Board, please inquire here to learn more about the BIO Board nomination process:

Inquire about BIO Board Nominations

If you have any questions about the BIO Board of Directors, please contact Peter McHugh at pmchugh@bio.org.

For reference, a diagram of the Board and Committee structure is presented below.

Board and Committee structure

 

Executive Committee

Executive Committee

  • John Maraganore, PhD Chair
    CEO, Alnylam Pharmaceuticals, Inc
  • Ron Cohen, MD Immediate Past Chair
    CEO, Acorda Therapeutics, Inc
  • Bradford A. Zakes, MBA Treasurer
    Chief Executive Officer, Cerevast Therapeutics, Inc
  • Julie L. Gerberding, MD, MPH Secretary
    Executive Vice President, Communications, Global Policy, and Population Health &, Merck
  • Bill Anderson
    CEO & Head of North American Commercial Operations, Genentech, A Member of the Roche Group
  • Stuart A. Arbuckle
    Executive Vice President and Chief Commercial Office, Vertex Pharmaceuticals Incorporated
  • Katrine Bosley
    Chief Executive Officer, Editas Medicine
  • Albert Bourla, PhD
    Chief Operating Officer, Pfizer Inc.
  • Tjerk de Ruiter
    Chief Executive Officer, Corbion
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Rachel K. King
    Founder & CEO, GlycoMimetics, Inc
  • Jeremy M. Levin
    Chairman & CEO, Ovid Therapeutics Inc.
  • Philip W. Miller
    Global Regulatory & Government Affairs Lead, Monsanto Company
  • Michael Narachi
    President and Chief Executive Officer, Orexigen Therapeutics, Inc
  • Richard Pops
    Chairman & CEO, Alkermes, Inc.
  • Alan Shaw, PhD
    President & CEO, Calysta
  • Christi L. Shaw
    SVP & President of Lilly Bio-Medicines, Eli Lilly and Company
  • Eddie J. Sullivan, PhD
    President & CEO, SAB Biotherapeutics
  • Section Governing Boards

    Emerging Companies Section Governing Board

  • Michael Narachi Chair
    President and Chief Executive Officer, Orexigen Therapeutics, Inc
  • Katrine Bosley ECS Vice Chair
    Chief Executive Officer, Editas Medicine
  • Martin Babler
    Chief Executive Officer, Principia Biopharma
  • Laura A. Berezin
    Partner, Cooley LLP
  • Abbie Celniker
    Partner, Third Rock Ventures, LLC
  • Jeffrey L. Cleland, PhD
    President & CEO, Graybug Vision, Inc.
  • Ron Cohen, MD
    CEO, Acorda Therapeutics, Inc
  • John F. Crowley, JD, MBA
    Chairman & CEO, Amicus Therapeutics, Inc
  • Bassil I. Dahiyat, PhD
    President & CEO, Xencor, Inc
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Mark Drozdowski
    Partner - Pharmaceuticals National Audit Leader, KPMG LLP
  • Deborah Dunsire, MD
    President & CEO, XTuit Pharmaceuticals, Inc
  • Maxine Gowen, PhD
    President & CEO, Trevena, Inc.
  • Peter S. Greenleaf
    Chairman & CEO, Sucampo Pharmaceuticals, Inc
  • Paul J. Hastings
    Chairman & CEO, Proteon Therapeutics
  • Russell H. Herndon
    President & CEO, Hydra Biosciences, Inc
  • Jeff B. Kindler
    Chief Executive Officer, Centrexion Therapeutics
  • Rachel K. King
    Founder & CEO, GlycoMimetics, Inc
  • Scott Koenig, MD, PhD
    President & CEO, MacroGenics, Inc
  • Nick Leschly
    President & CEO, bluebird bio
  • Jeremy M. Levin
    Chairman & CEO, Ovid Therapeutics Inc.
  • Ted W. Love, MD
    Chief Executive Officer, Global Blood Therapeutics
  • Sandy Macrae
    CEO, Sangamo Therapeutics, Inc.
  • David Main
    CEO, Aquinox Pharmaceuticals, Inc.
  • John Maraganore, PhD
    CEO, Alnylam Pharmaceuticals, Inc
  • Joel S. Marcus
    Chief Executive Officer, Alexandria Real Estate Equities, Inc
  • Jeffrey D. Marrazzo
    Co-Founder & CEO, Spark Therapeutics
  • Steven J. Mento, PhD
    President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
  • Kenneth I. Moch
    President & CEO, Cognition Therapeutics
  • Lonnie Moulder
    Chief Executive Officer, Tesaro, Inc.
  • Amir Nashat
    Principal, Polaris Venture Partners
  • William J. Newell, JD
    Chief Executive Officer, Sutro Biopharma, Inc
  • Carlos V. Paya, MD, PhD
    Chief Executive Officer, Immune Design Corporation
  • Adelene Q. Perkins
    CEO, Infinity Pharmaceuticals, Inc.
  • Anna Protopapas, MBA
    President & CEO, Mersana Therapeutics, Inc
  • Mark Pruzanski, MD
    Founder, President & CEO, Intercept Pharmaceuticals, Inc
  • Michael G. Raab
    Chief Executive Officer, Ardelyx Inc.
  • James Sapirstein, MBA, RPh
    CEO, Contravir Pharmaceuticals
  • George A. Scangos, PhD
    Chief Executive Officer, VIR Biotechnology, Inc.
  • Nancy Simonian, MD
    Chief Executive Officer, Syros Pharmaceuticals
  • Gil Van Bokkelen, PhD
    Chairman & CEO, Athersys, Inc
  • Timothy P. Walbert
    Chairman, President & CEO, Horizon Pharma, plc
  • Sue Washer, MBA
    President & CEO, Applied Genetic Technologies Corporation (AGTC)
  • Thomas G. Wiggans, MBA
    Founder & CEO, Dermira, Inc.
  • Robert J. Wills, PhD
    VP, Alliance Management - Business Development, Pharma Group, GTx, Inc
  • Bradford A. Zakes, MBA
    Chief Executive Officer, Cerevast Therapeutics, Inc
  • Food & Agriculture Section Governing Board

  • Eddie J. Sullivan, PhD Food & Ag Section Chair
    President & CEO, SAB Biotherapeutics
  • Philip W. Miller Food & Ag Section Vice Chair
    Global Regulatory & Government Affairs Lead, Monsanto Company
  • Paul Backman
    Head of Industry Relations, Syngenta
  • Jerry Flint, PhD
    Vice President of the Industry Affairs & Regulatory Group, DowDupont
  • Scott Holmstrom, PhD
    Senior Director, Late Stage External Innovation, Elanco
  • Dan Meagher, PhD
    President & CEO, Agrivida, Inc
  • Adam Monroe
    President, Americas, Novozymes
  • Daphne Preuss, PhD
    President & CEO, Chromatin, Inc
  • Tammy Lee Stanoch
    President & CEO, Recombinetics, Inc
  • Ronald L. Stotish, PhD
    Chief Executive Officer, Aqua Bounty Technologies, Inc
  • John R. Swart, PhD
    President, Exemplar Genetics, LLC
  • Frank Terhorst
    Global Head of Seeds, Bayer CropScience, Inc.
  • Health Section Governing Board

  • John Maraganore, PhD Chair
    CEO, Alnylam Pharmaceuticals, Inc
  • Ron Cohen, MD Immediate Past Chair
    CEO, Acorda Therapeutics, Inc
  • Michael Narachi Secretary
    President and Chief Executive Officer, Orexigen Therapeutics, Inc
  • Bill Anderson
    CEO & Head of North American Commercial Operations, Genentech, A Member of the Roche Group
  • Stuart A. Arbuckle
    Executive Vice President and Chief Commercial Office, Vertex Pharmaceuticals Incorporated
  • Martin Babler
    Chief Executive Officer, Principia Biopharma
  • Jean-Jacques Bienaime
    President & CEO, BioMarin Pharmaceutical, Inc
  • Katrine Bosley
    Chief Executive Officer, Editas Medicine
  • Albert Bourla, PhD
    Chief Operating Officer, Pfizer Inc.
  • Carsten Brunn
    Head of Pharmaceuticals, Americas Region, Bayer Corporation
  • Bill Campbell
    Sr. Vice President & General Manager, North America Commercial Operations, CSL Behring
  • Fabrice Chouraqui, PhD
    President, Novartis Pharmaceuticals Corporation
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Deborah Dunsire, MD
    President & CEO, XTuit Pharmaceuticals, Inc
  • Mark Enyedy
    President and Chief Executive Officer, ImmunoGen, Inc
  • William Fitzsimmons, MS, PharmD
    Divisional EVP for Global Regulatory Affairs & Global Clinical &Research Quality, Astellas Pharma Inc.
  • Barry Flannelly
    Executive Vice President & General Manager US, OSS Healthcare, Inc.
  • Scott Garland
    President, Relypsa, Inc
  • Julie L. Gerberding, MD, MPH
    Executive Vice President, Communications, Global Policy, and Population Health &, Merck
  • Maxine Gowen, PhD
    President & CEO, Trevena, Inc.
  • Paul J. Hastings
    President & CEO, Proteon Therapeutics
  • Christopher P. Healey
    VP, Public Affairs, Grifols
  • Russell H. Herndon
    President & CEO, Hydra Biosciences, Inc
  • Rachel K. King
    Founder & CEO, GlycoMimetics, Inc
  • Scott Koenig, MD, PhD
    President & CEO, MacroGenics, Inc
  • Joseph LaRosa
    Senior Vice President, General Counsel and Secretary, Regeneron Pharmaceuticals, Inc
  • John Lepore, MD
    SVP, R&D Pipeline, GlaxoSmithKline
  • Nick Leschly
    President & CEO, bluebird bio
  • Jeremy M. Levin
    Chairman & CEO, Ovid Therapeutics Inc.
  • Elizabeth Lewis
    Chief Counsel, Global Oncology Business Unit, Patient Advocacy, Takeda Oncology
  • Sabine Luik, MD, MPH
    Senior Vice President, Medicine and Regulatory Affairs, Boehringer Ingelheim
  • Kiran Mazumdar-Shaw
    Chairperson & Managing Director, Biocon Limited
  • Paul McKenzie, PhD
    EVP, Pharmaceutical Operations & Technology, Biogen
  • Clive A. Meanwell, MD, PhD
    Founder, Chairman & CEO, The Medicines Company
  • Steven J. Mento, PhD
    President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
  • Jim Meyers
    EVP, Worldwide Commercial Operations, Gilead Sciences, Inc
  • Kenneth I. Moch
    President & CEO, Cognition Therapeutics
  • Michael M. Morrissey, PhD
    President & CEO, Exelixis, Inc
  • William J. Newell, JD
    Chief Executive Officer, Sutro Biopharma, Inc
  • C. David Nicholson, PhD
    Chief R&D Officer, Allergan PLC
  • Joshua J. Ofman, MD
    Senior Vice President, Global Value, Access and Policy, Amgen Inc.
  • Carlos V. Paya, MD, PhD
    Chief Executive Officer, Immune Design Corporation
  • Adelene Q. Perkins
    CEO, Infinity Pharmaceuticals, Inc.
  • Anne Phillips, MD
    SVP, Clinical, Medical & Regulatory Affairs, Novo Nordisk
  • Richard Pops
    Chairman & CEO, Alkermes, Inc.
  • Shaji Procida
    President & COO, Eisai, Inc
  • Howard W. Robin
    President & CEO, Nektar Therapeutics, Inc
  • Michael Ryan, PhD
    SVP for US Value, Access, Pricing and Health Economics and Outcomes Research, Bristol-Myers Squibb Company
  • James Sapirstein, MBA, RPh
    CEO, Contravir Pharmaceuticals
  • Christi L. Shaw
    SVP & President of Lilly Bio-Medicines, Eli Lilly and Company
  • Bill Sibold
    Executive Vice President, Sanofi Genzyme
  • Nancy Simonian, MD
    Chief Executive Officer, Syros Pharmaceuticals
  • Mark Skaletsky
    Chairman & CEO, Fenway Pharmaceuticals, Inc
  • Scott Smith
    President and COO, Celgene Corporation
  • David M. Stack
    President & CEO, Pacira Pharmaceuticals, Inc.
  • Perry Sternberg
    Head, US Commercial, Shire
  • James Sullivan, PhD
    Vice President, Pharmaceutical Discovery, AbbVie Inc.
  • Jennifer Taubert
    Company Group Chairman, Pharmaceuticals, The Americas, Johnson & Johnson
  • Jean-Christophe Tellier, MD
    Chief Executive Officer & Chairman, UCB SA
  • Helen Torley, MRCP
    President, Chief Executive Officer, Halozyme Therapeutics, Inc
  • Mark Trudeau
    President & CEO, Mallinckrodt Pharmaceuticals
  • Gil Van Bokkelen, PhD
    Chairman & CEO, Athersys, Inc
  • Timothy P. Walbert
    Chairman, President & CEO, Horizon Pharma, plc
  • H. Thomas Watkins
    Chair Emeritus, BIO, Biotechnology Innovation Organization
  • Rick E. Winningham
    Chief Executive Officer, Theravance Biopharma US, Inc.
  • Gary Zieziula
    President & Managing Director, North America, EMD Serono, Inc
  • Industrial & Environmental Section Governing Board

  • Alan Shaw, PhD I&E Section Chair
    President & CEO, Calysta
  • Tjerk de Ruiter I&E Section Vice Chair
    Chief Executive Officer, Corbion
  • Doug Berven
    Vice President, Corporate Affairs, Poet, LLC
  • Jennifer Holmgren, MBA, PhD
    Chief Executive Officer, LanzaTech
  • Mark Jones, PhD
    Executive Strategy and Communications Director, The Dow Chemical Company
  • Benjamin R. Knudsen
    Head of Biotechnology NA/GM, BASF Enzymes LLC
  • John G. Melo
    Chief Executive Officer, Amyris, Inc.
  • Adam Monroe
    President, Americas, Novozymes
  • Vince Sewalt, PhD
    Senior Director, Product Stewardship & Regulatory, DowDupont
  • Christopher Standlee
    Vice President, ICM, Inc
  • Brian Thome
    Chief Executive Officer, Edeniq Inc.
  • Simon Waddington, PhD
    Chief Executive Officer, Evolva
  • Hugh C. Welsh, JD
    President, DSM North America
  • Roger Wyse, PhD
    Managing Director, Spruce Capital Partners